Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-XT771 PET in Glioblastoma and ccRCC
NCT07067905Phase 1Recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Jun 2025
- Primary completion
- Apr 2026
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial, sponsored by Chinese PLA General Hospital. Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 7 days. Started Jun 2025; status: recruiting.
Beyond the preview
Go deeper on NCT07067905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07067905.